510(k) DEN170046

23andMe PGS Genetic Health Risk Report for BRCA1/BRCA2 (Selected Variants) by 23AndMe, Inc. — Product Code QAZ

Clearance Details

Decision
DENG (De Novo Granted)
Decision Date
March 6, 2018
Date Received
September 5, 2017
Clearance Type
Direct
Expedited Review
No
Third Party Review
No

Device Classification

Device Name
Cancer Predisposition Risk Assessment System
Device Class
Class II
Regulation Number
866.6090
Review Panel
PA
Submission Type

A qualitative in vitro molecular diagnostic system used for the detection of select variants in specified cancer-related genes. The device is intended to be used on genomic DNA isolated from human specimens collected by the user. The results of the test provide users with a genetic health risk assessment for developing certain cancers. The test may not include all variants associated with a predisposition of developing cancer and is not intended to describe a person’s overall risk of developing any type of cancer nor to aid in determination of treatment or act as a substitute for recommended cancer screenings or appropriate follow-up. The device is for over-the-counter use.